Collaboration Arrangements (Tables)

12 Months Ended

Dec. 31, 2011

Collaboration Arrangements

Schedule of common stock shares purchased in private placements by the affiliate of GSK

	Through December 31, 2011
	Common Stock Shares Purchased		Aggregate Amounts (in thousands)
Purchase dates
February 24, 2011		152,278	$	3,609
May 3, 2011		261,299	$	6,689
August 2, 2011		102,466	$	2,020
November 1, 2011		58,411	$	1,298

Schedule of upfront license fees and milestone payments received from GSK under the LABA collaboration and strategic alliance agreements

	Through December 31, 2011
(in thousands)	Upfront License Fees		Milestone Payments		Total
GSK Collaborations
LABA/RELOVAIR™ collaboration(1)	$	10,000	$	50,000	$	60,000
Strategic alliance agreement		20,000		—		20,000
Strategic alliance—LAMA license(2)		5,000		3,000		8,000
Strategic alliance—MABA program license		6,000		16,000		22,000
Total	$	41,000	$	69,000	$	110,000

(1)

The Company does not currently expect to be eligible for any additional milestones under this collaboration.

(2)

In August 2004, GSK exercised its right to license the Company's LAMA program pursuant to the terms of the strategic alliance. In 2009, GSK returned the program to the Company.

Schedule of revenue recognized from GSK under the LABA collaboration and strategic alliance agreements

	Year Ended December 31,
(in thousands)	2011		2010		2009
LABA/RELOVAIR™ collaboration(1)	$	4,718	$	5,081	$	5,081
Strategic alliance agreement		1,858		2,738		2,738
Strategic alliance—LAMA license		—		—		4,240
Strategic alliance—MABA program license(2)		3,082		2,007		3,014
Total revenue	$	9,658	$	9,826	$	15,073

(1)

In the fourth quarter of 2011, the Company revised the estimated performance period for the LABA program based on its progress. The Company does not expect that the revisions will have a material impact on future revenue recognized under this program.

(2)

In the fourth quarter of 2011 and the first quarter of 2010, the Company revised the estimated performance period for the MABA program based on its progress. The Company does not expect that the revisions will have a material impact on future revenue recognized under this program.

Schedule of revenue recognized under the Astellas collaboration agreement

	December 31,
(in thousands)	2011			2010			2009
Amortization of deferred revenue	$	12,975		$	12,975		$	11,338
Royalties from net sales of VIBATIV®		2,422			1,123			766
Proceeds from VIBATIV® delivered to Astellas		1,171			2,058			—
Cost of VIBATIV® delivered to Astellas		(1,177	)		(938	)		(1,629	)
Cost of unrealizable VIBATIV® inventory		(537	)		(821	)		(1,175	)
Total net revenue	$	14,854		$	14,397		$	9,300